Cardiff Oncology Inc

CRDF remains in Stage 4 decline with medium-term bearish bias—execution should focus on trimming into rallies around the declining 9/21 EMA zone and prior consolidation highs. Short-term timing is neutral amid extreme oversold conditions, suggesting deferred engagement until relief bounces stall.

• ↑Onvansertib achieved 64% ORR vs 33% control in CARTF004 trial
• ↑Pfizer Ignite partnership enhances trial execution efficiency
• ↓Negative profitability profile with weak margins and earnings yield